Italian real life experience with brentuximab vedotin

Cinzia Pellegrini; Alessandro Broccoli; Alessandro Pulsoni; Luigi Rigacci; Caterina Patti; Guido Gini; Donato Mannina; Monica Tani; Chiara Rusconi; Alessandra Romano; Anna Vanazzi; Barbara Botto; Armando Santoro; Stefan Hoaus; Gian Matteo Rigolin; Pellegrino Musto; Patrizio Mazza; Stefano Molica; Paolo Corradini; Angelo Fama; Francesco Gaudio; Michele Merli; Fioravante Ronconi; Giuseppe Gritti; Daniele Vallisa; Patrizia Tosi; Anna Marina Liberati; Antonello Pinto; Vincenzo Pavone; Filippo Gherlinzoni; Maria Paola Bianchi; Stefano Volpetti; Livio Trentin; Maria Cecilia Goldaniga; Maurizio Bonfichi; Amalia De Renzo; Corrado Schiavotto; Michele Spina; Angelo Michele Carella; Vittorio Stefoni; Lisa Argnani; Pier Luigi Zinzani

Italian real life experience with brentuximab vedotin

Cinzia Pellegrini, Alessandro Broccoli, Alessandro Pulsoni, Luigi Rigacci, Caterina Patti, Guido Gini, Donato Mannina, Monica Tani, Chiara Rusconi, Alessandra Romano, Anna Vanazzi, Barbara Botto, Armando Santoro, Stefan Hoaus, Gian Matteo Rigolin, Pellegrino Musto, Patrizio Mazza, Stefano Molica, Paolo Corradini, Angelo FamaFrancesco Gaudio, Michele Merli, Fioravante Ronconi, Giuseppe Gritti, Daniele Vallisa, Patrizia Tosi, Anna Marina Liberati, Antonello Pinto, Vincenzo Pavone, Filippo Gherlinzoni, Maria Paola Bianchi, Stefano Volpetti, Livio Trentin, Maria Cecilia Goldaniga, Maurizio Bonfichi, Amalia De Renzo, Corrado Schiavotto, Michele Spina, Angelo Michele Carella, Vittorio Stefoni, Lisa Argnani, Pier Luigi Zinzani

Research output: Contribution to journal › Article › peer-review

Abstract

A large Italian multicenter observational retrospective study was conducted on the use of brentuximab vedotin (BV) for patients with relapsed Hodgkin's lymphoma (HL) to check if clinical trial results are confirmed even in a real life context. 234 CD30+ HL patients were enrolled. Best response was observed after a median of 4 cycles in 140 patients (59.8%): 74 (31.6%) patients obtained a complete response (CR) and 66 (28.2%) achieved a partial response (PR); overall response rate at the end of the treatment was 48.3% (62 CR and 51 PR). The best response rate was higher in the elderly subset: 14 (50%) CR and 5 (17.8%) PR. Disease free survival was 26.3% at 3 years and progression free survival 31.9% at 4.5 years. Duration of response did not differ for who achieved at least PR and then either did or did not undergo consolidative transplant. Overall, the treatment was well tolerated and no death has been linked to BV-induced toxicity. Our report confirms activity in elderly patients, duration of response unrelated to the consolidation with transplant procedure, the relevance of the CR status at first restaging, and the role of BV as a bridge to transplant for chemorefractory patients.

Original language	English
Pages (from-to)	91703-91710
Number of pages	8
Journal	Oncotarget
Volume	8
Issue number	53
Publication status	Published - Oct 31 2017

Keywords

Journal Article

Fingerprint Dive into the research topics of 'Italian real life experience with brentuximab vedotin'. Together they form a unique fingerprint.

Cite this

Italian real life experience with brentuximab vedotin. / Pellegrini, Cinzia; Broccoli, Alessandro; Pulsoni, Alessandro; Rigacci, Luigi; Patti, Caterina; Gini, Guido; Mannina, Donato; Tani, Monica; Rusconi, Chiara; Romano, Alessandra; Vanazzi, Anna; Botto, Barbara; Santoro, Armando; Hoaus, Stefan; Rigolin, Gian Matteo; Musto, Pellegrino; Mazza, Patrizio; Molica, Stefano; Corradini, Paolo ; Fama, Angelo; Gaudio, Francesco; Merli, Michele; Ronconi, Fioravante; Gritti, Giuseppe; Vallisa, Daniele; Tosi, Patrizia; Liberati, Anna Marina; Pinto, Antonello; Pavone, Vincenzo; Gherlinzoni, Filippo; Bianchi, Maria Paola; Volpetti, Stefano; Trentin, Livio; Goldaniga, Maria Cecilia ; Bonfichi, Maurizio; De Renzo, Amalia; Schiavotto, Corrado; Spina, Michele ; Carella, Angelo Michele; Stefoni, Vittorio; Argnani, Lisa; Zinzani, Pier Luigi.

In: Oncotarget, Vol. 8, No. 53, 31.10.2017, p. 91703-91710.

Research output: Contribution to journal › Article › peer-review

Pellegrini, C, Broccoli, A, Pulsoni, A, Rigacci, L, Patti, C, Gini, G, Mannina, D, Tani, M, Rusconi, C, Romano, A, Vanazzi, A, Botto, B, Santoro, A, Hoaus, S, Rigolin, GM, Musto, P, Mazza, P, Molica, S, Corradini, P , Fama, A, Gaudio, F, Merli, M, Ronconi, F, Gritti, G, Vallisa, D, Tosi, P, Liberati, AM, Pinto, A, Pavone, V, Gherlinzoni, F, Bianchi, MP, Volpetti, S, Trentin, L, Goldaniga, MC , Bonfichi, M, De Renzo, A, Schiavotto, C, Spina, M , Carella, AM, Stefoni, V, Argnani, L & Zinzani, PL 2017, 'Italian real life experience with brentuximab vedotin', Oncotarget, vol. 8, no. 53, pp. 91703-91710.

Pellegrini, Cinzia ; Broccoli, Alessandro ; Pulsoni, Alessandro ; Rigacci, Luigi ; Patti, Caterina ; Gini, Guido ; Mannina, Donato ; Tani, Monica ; Rusconi, Chiara ; Romano, Alessandra ; Vanazzi, Anna ; Botto, Barbara ; Santoro, Armando ; Hoaus, Stefan ; Rigolin, Gian Matteo ; Musto, Pellegrino ; Mazza, Patrizio ; Molica, Stefano ; Corradini, Paolo ; Fama, Angelo ; Gaudio, Francesco ; Merli, Michele ; Ronconi, Fioravante ; Gritti, Giuseppe ; Vallisa, Daniele ; Tosi, Patrizia ; Liberati, Anna Marina ; Pinto, Antonello ; Pavone, Vincenzo ; Gherlinzoni, Filippo ; Bianchi, Maria Paola ; Volpetti, Stefano ; Trentin, Livio ; Goldaniga, Maria Cecilia ; Bonfichi, Maurizio ; De Renzo, Amalia ; Schiavotto, Corrado ; Spina, Michele ; Carella, Angelo Michele ; Stefoni, Vittorio ; Argnani, Lisa ; Zinzani, Pier Luigi. / Italian real life experience with brentuximab vedotin. In: Oncotarget. 2017 ; Vol. 8, No. 53. pp. 91703-91710.

@article{0a635e4e456346d781a3930c02218eaf,

title = "Italian real life experience with brentuximab vedotin",

abstract = "A large Italian multicenter observational retrospective study was conducted on the use of brentuximab vedotin (BV) for patients with relapsed Hodgkin's lymphoma (HL) to check if clinical trial results are confirmed even in a real life context. 234 CD30+ HL patients were enrolled. Best response was observed after a median of 4 cycles in 140 patients (59.8%): 74 (31.6%) patients obtained a complete response (CR) and 66 (28.2%) achieved a partial response (PR); overall response rate at the end of the treatment was 48.3% (62 CR and 51 PR). The best response rate was higher in the elderly subset: 14 (50%) CR and 5 (17.8%) PR. Disease free survival was 26.3% at 3 years and progression free survival 31.9% at 4.5 years. Duration of response did not differ for who achieved at least PR and then either did or did not undergo consolidative transplant. Overall, the treatment was well tolerated and no death has been linked to BV-induced toxicity. Our report confirms activity in elderly patients, duration of response unrelated to the consolidation with transplant procedure, the relevance of the CR status at first restaging, and the role of BV as a bridge to transplant for chemorefractory patients.",

keywords = "Journal Article",

author = "Cinzia Pellegrini and Alessandro Broccoli and Alessandro Pulsoni and Luigi Rigacci and Caterina Patti and Guido Gini and Donato Mannina and Monica Tani and Chiara Rusconi and Alessandra Romano and Anna Vanazzi and Barbara Botto and Armando Santoro and Stefan Hoaus and Rigolin, {Gian Matteo} and Pellegrino Musto and Patrizio Mazza and Stefano Molica and Paolo Corradini and Angelo Fama and Francesco Gaudio and Michele Merli and Fioravante Ronconi and Giuseppe Gritti and Daniele Vallisa and Patrizia Tosi and Liberati, {Anna Marina} and Antonello Pinto and Vincenzo Pavone and Filippo Gherlinzoni and Bianchi, {Maria Paola} and Stefano Volpetti and Livio Trentin and Goldaniga, {Maria Cecilia} and Maurizio Bonfichi and {De Renzo}, Amalia and Corrado Schiavotto and Michele Spina and Carella, {Angelo Michele} and Vittorio Stefoni and Lisa Argnani and Zinzani, {Pier Luigi}",

year = "2017",

month = oct,

day = "31",

language = "English",

volume = "8",

pages = "91703--91710",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals LLC",

number = "53",

}

TY - JOUR

T1 - Italian real life experience with brentuximab vedotin

AU - Pellegrini, Cinzia

AU - Broccoli, Alessandro

AU - Pulsoni, Alessandro

AU - Rigacci, Luigi

AU - Patti, Caterina

AU - Gini, Guido

AU - Mannina, Donato

AU - Tani, Monica

AU - Rusconi, Chiara

AU - Romano, Alessandra

AU - Vanazzi, Anna

AU - Botto, Barbara

AU - Santoro, Armando

AU - Hoaus, Stefan

AU - Rigolin, Gian Matteo

AU - Musto, Pellegrino

AU - Mazza, Patrizio

AU - Molica, Stefano

AU - Corradini, Paolo

AU - Fama, Angelo

AU - Gaudio, Francesco

AU - Merli, Michele

AU - Ronconi, Fioravante

AU - Gritti, Giuseppe

AU - Vallisa, Daniele

AU - Tosi, Patrizia

AU - Liberati, Anna Marina

AU - Pinto, Antonello

AU - Pavone, Vincenzo

AU - Gherlinzoni, Filippo

AU - Bianchi, Maria Paola

AU - Volpetti, Stefano

AU - Trentin, Livio

AU - Goldaniga, Maria Cecilia

AU - Bonfichi, Maurizio

AU - De Renzo, Amalia

AU - Schiavotto, Corrado

AU - Spina, Michele

AU - Carella, Angelo Michele

AU - Stefoni, Vittorio

AU - Argnani, Lisa

AU - Zinzani, Pier Luigi

PY - 2017/10/31

Y1 - 2017/10/31

N2 - A large Italian multicenter observational retrospective study was conducted on the use of brentuximab vedotin (BV) for patients with relapsed Hodgkin's lymphoma (HL) to check if clinical trial results are confirmed even in a real life context. 234 CD30+ HL patients were enrolled. Best response was observed after a median of 4 cycles in 140 patients (59.8%): 74 (31.6%) patients obtained a complete response (CR) and 66 (28.2%) achieved a partial response (PR); overall response rate at the end of the treatment was 48.3% (62 CR and 51 PR). The best response rate was higher in the elderly subset: 14 (50%) CR and 5 (17.8%) PR. Disease free survival was 26.3% at 3 years and progression free survival 31.9% at 4.5 years. Duration of response did not differ for who achieved at least PR and then either did or did not undergo consolidative transplant. Overall, the treatment was well tolerated and no death has been linked to BV-induced toxicity. Our report confirms activity in elderly patients, duration of response unrelated to the consolidation with transplant procedure, the relevance of the CR status at first restaging, and the role of BV as a bridge to transplant for chemorefractory patients.

AB - A large Italian multicenter observational retrospective study was conducted on the use of brentuximab vedotin (BV) for patients with relapsed Hodgkin's lymphoma (HL) to check if clinical trial results are confirmed even in a real life context. 234 CD30+ HL patients were enrolled. Best response was observed after a median of 4 cycles in 140 patients (59.8%): 74 (31.6%) patients obtained a complete response (CR) and 66 (28.2%) achieved a partial response (PR); overall response rate at the end of the treatment was 48.3% (62 CR and 51 PR). The best response rate was higher in the elderly subset: 14 (50%) CR and 5 (17.8%) PR. Disease free survival was 26.3% at 3 years and progression free survival 31.9% at 4.5 years. Duration of response did not differ for who achieved at least PR and then either did or did not undergo consolidative transplant. Overall, the treatment was well tolerated and no death has been linked to BV-induced toxicity. Our report confirms activity in elderly patients, duration of response unrelated to the consolidation with transplant procedure, the relevance of the CR status at first restaging, and the role of BV as a bridge to transplant for chemorefractory patients.

KW - Journal Article

M3 - Article

VL - 8

SP - 91703

EP - 91710

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 53

ER -